GLP-1, amylin, and multi-agonist compounds.

GLP-1 and metabolic research peptides are incretin-pathway agonists studied in preclinical research models for their effects on glucose-stimulated signaling, satiety pathways, and dual/triple receptor pharmacology. The Nexus catalog includes 9 compounds in this category — examples: Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Mazdutide — supplied for in-vitro research use only with public COA status visible on product pages. GLP-1 and metabolic research compounds are used to study incretin signaling, amylin-pathway activity, and newer multi-agonist receptor models. This Nexus category groups single-pathway GLP-1 analogs with dual and triple agonist research tools so qualified buyers can compare formats without jumping across the catalog. The category includes established GLP-1 research references, amylin analogs, and blended metabolic models. Product pages remain research-use focused and avoid therapeutic positioning; the emphasis is on identity, vial format, COA visibility, and batch-level verification.

Researchers in this category commonly compare receptor selectivity, agonist families, concentration-response models, and stability across related incretin or amylin-pathway compounds. GLP-1 analogs are often evaluated alongside GIP, glucagon, or amylin activity depending on the product family and experimental design. Because this category includes single agents and combination formats, product-page clarity matters. Nexus separates individual compounds from blends, lists variant sizes, and links COA records where available so researchers can distinguish catalog identity from downstream experimental use. Claims are intentionally limited to research context rather than outcomes.

Nexus prioritizes batch visibility, HPLC purity context, and lab-tested identity records for metabolic research compounds. Product pages surface COA links, variant SKUs, and research-only handling language so buyers can evaluate the record before purchase. Final signed lot files should be confirmed before production launch.

Compounds in this category are studied in preclinical research models examining the incretin axis — GLP-1, GIP, glucagon, and amylin receptor pharmacology. Common research applications include single-receptor pharmacology (semaglutide and liraglutide as GLP-1 reference agonists), dual-receptor comparison studies (tirzepatide for GIP/GLP-1, mazdutide and survodutide for GLP-1/glucagon), triple-receptor research (retatrutide), and multi-pathway combinations using amylin agonists alongside incretin agonists (cagri-sema, retatrutide+cagrilintide). The category is the largest contemporary research peptide family by published literature volume; receptor pharmacology research alone has produced more than a thousand peer-reviewed studies since 2017.

The nine compounds in this category span a structural range: peptide single agonists (semaglutide, liraglutide), peptide dual agonists (tirzepatide for GIP/GLP-1; mazdutide and survodutide for GLP-1/glucagon), triple agonists (retatrutide), an amylin analog (cagrilintide), and pre-mixed blends (cagri-sema, retatrutide+cagrilintide). Half-lives range from sub-day (liraglutide) to multi-day (semaglutide, tirzepatide), and molecular weight ranges from ~3.5 kDa (liraglutide, cagrilintide) to ~4.8 kDa (tirzepatide).

Common research-stack pairings in this category: semaglutide + cagrilintide (cagri-sema research blend), retatrutide + cagrilintide (multi-receptor + amylin research), and head-to-head comparator studies pairing semaglutide vs tirzepatide or tirzepatide vs retatrutide. Researchers commonly study one single-agonist and one multi-agonist side-by-side in the same experiment.

GLP-1 family peptides are large (3.5-4.8 kDa) and require deconvoluted electrospray-ionization mass spectrometry for identity confirmation. Acetate salt form is standard; HPLC purity target is ≥98%. Finalized COA records publish endotoxin context where available, while pending certificates withhold assay values until release.